SOURCE: HealthCare Purchasing Partners International

April 19, 2005 09:00 ET

HealthCare Purchasing Partners International™ Adds Novo Nordisk to Growing List of Companies Providing Low-Cost Drugs to Clinics, Hospitals and Programs for Low-Income Americans

DALLAS, TX -- (MARKET WIRE) -- April 19, 2005 -- HealthCare Purchasing Partners International™ (HPPI) announced today that it has added Novo Nordisk to its growing list of health care companies providing drugs, supplies and medical devices to clinics, hospitals and health care programs for low-income and uninsured Americans.

HPPI, a group purchasing organization co-owned by VHA Inc. and the University HealthSystem Consortium, signed Novo Nordisk to the federal program that HPPI began managing exclusively in September. The program, known as the 340B Prime Vendor Program, provides deep discounts on outpatient drug purchases to public hospitals, community health centers, clinics, state-operated AIDS drug assistance programs and other safety-net health care providers serving low income and uninsured patients.

Novo Nordisk will provide an array of insulins and other products used for the management of diabetes. These include:

--  Rapid Acting Insulin - Analog (vials, FlexPen and Cartridges)
--  Human Insulin (vials and pre-filled disposable delivery doser)
--  Mix Insulin - Analog (vials, FlexPen and Cartridges)
--  Disposable needles
--  Repaglinide tablets
"We are pleased to add Novo Nordisk's line of products to treat diabetes to the 340B Prime Vendor Progam," said Chris Hatwig, senior director of the Prime Vendor Program for HPPI. "This will help provide life-saving and affordable medication to the patients who need it most."

The Prime Vendor Program was established to increase the discounts already offered under Section 340B of the U.S. Public Health Service Act. HPPI was selected from competing GPOs and other companies to administer the program. Hatwig said that 11,800 providers across the country qualify to participate in the discount program at no cost, and more than 1,000 facilities are currently enrolled.

"As a health care company, Novo Nordisk is dedicated to providing access to the highest quality diabetes care and treatments in innovative delivery systems for the millions of people living with diabetes," said Martin Soeters, president of Novo Nordisk Inc. "Joining efforts with HPPI furthers our commitment to social responsibility by addressing the needs of communities that are underserved and disproportionately affected by diabetes."

About HPPI

HealthCare Purchasing Partners International (HPPI) is an Irving, Texas-based health care group purchasing organization serving more than 8,000 health care organizations across the nation. HPPI members used its contracts to purchase more than $2.2 billion in supplies in 2003. HPPI is owned by VHA Inc., a national health care cooperative, and the University HealthSystem Consortium (UHC), an alliance of academic medical centers. HPPI was formed by VHA and UHC to serve health care organizations that do not belong to either VHA or UHC.

About Novo Nordisk Inc.

Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. With headquarters in Denmark, Novo Nordisk employs approximately 20,250 full-time employees in 78 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol 'NVO'. For more information, visit

Contact Information